Immutep 미래 성장

Future 기준 확인 2/6

Immutep (는) 각각 연간 1.1% 및 52.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -75.1% 로 예상됩니다.

주요 정보

1.1%

수익 성장률

7.2%

EPS 성장률

Biotechs 수익 성장	26.8%
매출 성장률	52.5%
향후 자기자본 수익률	-75.1%
애널리스트 커버리지	Low
마지막 업데이트	16 Dec 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Oct 04

Immutep secures €1.8M cash in French government's research tax credit

Sep 23

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Aug 30

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Jul 06

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Jun 12

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Mar 21

Immutep expands the evaluation of efti into a triple combination therapy, shares down 12%

Jun 21

Immutep reveals anti-LAG-3 research program

Jun 08

Immutep jumps 9% on Chinese patent for efti in chemo-immunotherapy combination

May 26

Immutep completes recruitment in efti mid-stage study in head & neck cancer

Jan 07

수익 및 매출 성장 예측

NasdaqGM:IMMP - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
6/30/2027	42	-39	-76	-39	3
6/30/2026	5	-70	-76	-76	3
6/30/2025	5	-65	-82	-68	3
6/30/2024	4	-43	-36	-35	N/A
3/31/2024	4	-42	-39	-38	N/A
12/31/2023	4	-41	-42	-42	N/A
9/30/2023	4	-40	-39	-39	N/A
6/30/2023	4	-40	-35	-35	N/A
3/31/2023	4	-38	-33	-33	N/A
12/31/2022	4	-37	-30	-30	N/A
9/30/2022	5	-34	-30	-30	N/A
6/30/2022	5	-32	-30	-30	N/A
3/31/2022	4	-29	-25	-25	N/A
12/31/2021	4	-26	-20	-20	N/A
9/30/2021	4	-28	-19	-19	N/A
6/30/2021	4	-30	-18	-18	N/A
3/31/2021	5	-29	-16	-16	N/A
12/31/2020	6	-27	-15	-15	N/A
9/30/2020	10	-20	-13	-13	N/A
6/30/2020	14	-13	-11	-11	N/A
3/31/2020	13	-15	-13	-13	N/A
12/31/2019	13	-16	-14	-14	N/A
9/30/2019	9	-17	-15	-15	N/A
6/30/2019	6	-18	-15	-15	N/A
3/31/2019	5	-18	-13	-13	N/A
12/31/2018	5	-17	-10	-10	N/A
9/30/2018	6	-15	-9	-9	N/A
6/30/2018	7	-13	-8	-8	N/A
3/31/2018	6	-12	N/A	-8	N/A
12/31/2017	7	-10	N/A	-8	N/A
9/30/2017	5	-9	N/A	-8	N/A
6/30/2017	4	-9	N/A	-9	N/A
3/31/2017	3	-10	N/A	-8	N/A
12/31/2016	2	-10	N/A	-9	N/A
9/30/2016	2	-36	N/A	-10	N/A
6/30/2016	2	-62	N/A	-11	N/A
3/31/2016	2	-71	N/A	-10	N/A
12/31/2015	1	-82	N/A	-8	N/A
9/30/2015	1	-57	N/A	-8	N/A
6/30/2015	1	-32	N/A	-8	N/A
3/31/2015	1	-23	N/A	-10	N/A
12/31/2014	1	-14	N/A	-13	N/A
9/30/2014	2	-14	N/A	-13	N/A
6/30/2014	2	-13	N/A	-14	N/A
3/31/2014	2	-13	N/A	-14	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IMMP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: IMMP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: IMMP 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: IMMP 의 수익(연간 52.5% ) US 시장( 9% 보다 빠르게 성장할 것으로 예상됩니다. 9% 연간).

고성장 수익: IMMP 의 수익(연간 52.5% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IMMP (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/05 09:02
장 마감 주가	2025/01/03 00:00
수익	2024/06/30
연간 수익	2024/06/30

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Immutep Limited 17 애널리스트 중 4 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Joel Beatty	Baird
Thomas Wakim	Bell Potter
Tara Speranza	Bell Potter

Immutep 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

Immutep Limited and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

Immutep Limited Reports Promising New Data in Head and Neck Cancer At ESMO Immuno-Oncology 2024

Immutep Limited Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

Immutep: Potential Of Efti As New Standard Of Care For NSCLC Patients

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep: Positive Efti Treatment Data Leads To Late-Stage Programs

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Immutep: Realizing The Expected Catalysts, With More To Come

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Immutep Limited, Annual General Meeting, Oct 24, 2023

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Immutep stock climbs on FDA fast track status for eftilagimod to treat lung cancer subtype

Immutep secures €1.8M cash in French government's research tax credit

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Announces Investigator-Initiated Phase Ii Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Immutep Limited Grants Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor

Immutep gets Japanese patent for immunotherapy eftilagimod alpha combo

Immutep Limited Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, eftilagimod alpha and IMP76 for the Quarter Ended 30 June 2022

Immutep gets Japanese patent related to autoimmune disease drug candidate IMP761

Immutep: Australian Immune-Focused Company, Pureplay LAG3 Player

Immutep Limited Reports Positive Overall Response Rate in Its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

Immutep Limited Announces Executive Changes

Immutep Limited Presents New and Significant Data from the AIPAC Study

Immutep Limited Provides Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha and IMP761 for the Quarter Ended 31 March 2022

Immutep’S Efti in Combination with Msd’S Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2Nd Line Metastatic Lung Cancer Patients

Immutep Limited Announces New Interim Data in 2nd Line Metastatic NSCLC from Its Phase II TACTI-002 Trial

Immutep - LAG3 Checkpoint Receives First FDA Approval; Positive For This LAG3 Pure Play

Immutep Limited Appoints Lucy Turnbull as Non-Executive Director

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

Immutep Limited to Present New Data from the Phase II TACTI-002 Study of Efti At ESMO's European Lung Cancer Congress 2022

Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates, Eftilagimod Alpha

Immutep Limited Reports Good Safety from First Five Patients in the INSIGHT-003 study

Immutep to Present Final Overall Survival Data from Phase IIb AIPAC as a Late Breaking Poster Presentation At SITC 2021

Immutep Limited Provides an Update on the Ongoing Development of Its Product Candidates